Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
Merck & Co., Inc. director Paul Rothman reported compensation-related equity activity. He received a grant of 1,853.0997 phantom stock units tied to Merck common stock at a reference price of $118.7200 per unit.
After this grant, his phantom stock holdings total 34,944.9417 units, which are to be settled 100% in cash upon his termination of service under the Plan for Deferred Payment of Directors' Compensation. He also reports direct ownership of 100 shares of Merck common stock, including shares acquired through dividend reinvestment transactions.
Merck & Co., Inc. director Stephen Mayo reported a compensation-related award of phantom stock units linked to the company’s common stock. He received 1,853.0997 phantom stock units, which are tied 1-for-1 to Merck common shares and are to be settled 100% in cash after his service ends under a deferred compensation plan. Following this award, he holds 14,824.5202 phantom stock units and 100 shares of Merck common stock, with the share holdings including amounts acquired through dividend reinvestment transactions.
LAVIZZO-MOUREY RISA J reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Risa J. Lavizzo-Mourey reported a compensation-related award of phantom stock units rather than a market trade. She received 1,853.0997 phantom stock units tied on a 1-for-1 basis to Merck common stock at a reference price of $118.72 per unit, increasing her phantom stock balance to 17,749.3517 units. These units are designed to be settled 100% in cash after her service ends, under the Plan for Deferred Payment of Directors' Compensation. The filing also notes she directly holds 1,000 shares of Merck common stock, including shares accumulated through dividend reinvestment.
GLOCER THOMAS H reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Thomas H. Glocer reported updated holdings, including a new grant of phantom stock units tied to the company’s common shares. He received 1853.0997 phantom stock units, each tracked on a 1-for-1 basis to Merck common stock and awarded at a reference price of $118.7200 per unit.
Following this grant, Glocer holds 110911.7587 phantom stock units, which are to be settled entirely in cash after his termination of service under the Plan for Deferred Payment of Directors' Compensation. His direct common stock holdings total 5100.0000 shares, including shares accumulated through dividend reinvestment transactions.
Craig Pamela J. reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Pamela J. Craig reported a compensation-related award of phantom stock units and updated share holdings. She received 1,853.0997 phantom stock units, each valued at $118.72 per unit on the grant date, increasing her phantom stock balance to 34,944.9297 units. These units track Merck common stock on a 1-for-1 basis but are designed to be settled 100% in cash after her service ends, under the Plan for Deferred Payment of Directors' Compensation. Following the transactions, she also directly holds 1,715 shares of Merck common stock, which includes shares accumulated through dividend reinvestment.
Merck & Co., Inc. director Douglas M. Baker Jr. reported updated holdings and a new compensation award. He now directly holds 16,000 shares of Common Stock, which the filing notes include shares acquired through dividend reinvestment transactions. He also received a grant of 1,853.0997 Phantom Stock units, bringing his Phantom Stock balance to 11,518.2084 units.
The Phantom Stock units reference Merck common shares on a 1-for-1 basis at a value of $118.72 per unit but are designed to be settled entirely in cash after his service ends, following a distribution schedule elected under the Plan for Deferred Payment of Directors' Compensation.
Merck & Co., Inc. reported the results of shareholder voting from its Annual Meeting of Shareholders held on May 26, 2026. The report focuses on the submission of matters to a vote of security holders.
Shareholders cast detailed votes for the election of 13 directors, with each nominee receiving over 1.6 billion votes "For" and significant broker non-votes of 283,983,197 reported for each director. The company states that a majority of the votes cast was required for all six proposals presented at the meeting.
Merck & Co., Inc. closed an underwritten public offering of several series of senior notes. The company issued $500,000,000 of Floating Rate Notes due 2028, $1,000,000,000 of 4.300% Notes due 2028, and $500,000,000 of 4.650% Notes due 2031.
Merck also issued $1,000,000,000 of 4.950% Notes due 2033, $1,500,000,000 of 5.200% Notes due 2036, $500,000,000 of 5.750% Notes due 2046, and $1,000,000,000 of 5.850% Notes due 2056 under an existing shelf registration and a 2010 indenture.
Merck & Co., Inc. is offering $6,000,000,000 of unsecured senior notes across seven series comprising floating-rate and fixed-rate maturities from May 22, 2028 through May 22, 2056. The prospectus supplement states net proceeds, estimated at approximately $5.96 billion, will be used to repay in full borrowings under a 364‑day delayed draw term loan credit agreement incurred to finance the acquisition of Terns Pharmaceuticals, Inc.
The offering lists series sizes and coupons explicitly (for example, $1.5 billion 5.200% notes due 2036 and $500 million floating‑rate notes due 2028), interest payment dates, optional redemption mechanics for fixed rate series and that the floating rate notes use Compounded SOFR + 0.370% (subject to benchmark‑replacement provisions). The notes will be unsecured, rank equally with other unsecured indebtedness and are not listed on an exchange.
Merck & Co., Inc. proposes a multi‑series debt offering of unsecured senior notes, including a floating‑rate series tied to Compounded SOFR and several fixed‑rate series, to be issued in minimum denominations of $2,000. Net proceeds are intended to repay borrowings under a 364‑Day Delayed Draw Term Loan Credit Agreement entered to finance the acquisition of Terns Pharmaceuticals, Inc., which closed on May 5, 2026. The prospectus supplement discloses the Terns acquisition consideration of $53.00 per share for an approximate equity value of $6.7 billion, and states the notes will rank equally with other unsecured senior indebtedness and be structurally subordinated to subsidiaries’ liabilities.